SP1和UBE2C在食管鳞癌中的表达与临床病理特征的相关性研究

doi:10.3969/j.issn.1006-6233.2025.11.027

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1509 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的: 探讨食管鳞状细胞癌(ESCC)组织中SP1、UBE2C表达水平与患者临床病理参数的相关性,评估其对预后的预测价值。方法: 选取2019年1月至2022年1承德市中心医院行手术治疗的ESCC患者127例的癌组织,同时选取癌旁正常鳞状上皮组织65例及选取58例食管鳞状上皮乳头状瘤组织。采用免疫组化(Envision 法)及实时定量PCR(RT-PCR)法测定观察组及对照组中SP1和UBE2C的表达水平,观察二者在ESCC组织、鳞状上皮乳头状瘤及癌旁正常食管黏膜组织中的表达情况,并分析其与临床病理特征的关系。结果: 试验组的SP1、UBE2C mRNA表达水平均高于对照组(均P<0.05),免疫组织化学染色结果也提示试验组的SP1、UBE2C的表达均高于对照组,差异具有统计学意义(均P<0.05)。ESCC组织中SP1和UBE2C表达水平与患者性别、年龄无关(P>0.05),与吸烟史、饮酒史、分化程度、TNM分期、淋巴结转移密切相关(P<0.05)。结论: SP1和UBE2C的阳性表达可能与ESCC发生及发展相关,因此,SP1和UBE2C有可能作为新的潜在治疗靶点,为ESCC患者的个体化治疗提供新的方向。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ：食管鳞状细胞癌, 鳞状上皮乳头状瘤, SP1, UBE2C, 临床病理特征

Abstract：Objective: To investigate the correlation between the expression levels of SP1, UBE2C in esophageal squ cell carcinoma (ESCC) tissues and the clinical pathological parameters of patients and to evaluate its predictive value for prognosis. Methods: A total of 127 ES patients who underwent surgical treatment in Central Hospital of Chengde from January 2019 to January 2022 were selected, along with 65 cases of squamous epithelium tissues adjacent to the tumor and 58 cases of esophageal squamous epithelial papilloma tissues. The expression levels of SP1 andBE2C in the observation group and the control group were determined by immunohistochemistry (Envision method) and real-time quantitative PCR (RT-PCR), the expression of the two in ESCC tissues, squamous epithelial papilloma and normal esophageal mucosa tissues adjacent to the tumor was observed, and its correlation with the clinical pathological characteristics was analyzed. Results: The mRNA expression levels of SP1 and UBE2C in the experimental group were higher than those in the control group ( P<0.05), and the results of immunohistochemical staining also showed that the expression levels of SP1 and UBE2C in the experimental were higher than those in the control group, with statistically significant differences (all P<0.05). The expression levels of SP1 and UBE2C inCC tissues were not related to the patient's gender and age (P>0.05), but closely related to the history of smoking, drinking, differentiation degree TNM staging, and lymph node metastasis (P<0.05). Conclusion: Positive expression of SP1 and UBE2C may be related to the and development of ESCC, therefore, SP1 and UBE2C may be used as new potential therapeutic targets, providing new directions for individualized treatment of ESCC patients.

Key words： Esophageal squamous cell carcinoma Squamous papilloma SP1 UBE2C Clinical pathological features

基金资助:河北省医学科学研究重点课题,(编号:20160298)

通讯作者: 王建祥

引用本文:

姜海斌, 吴建龙, 张冰心, 宋晶晶, 初晓燕, 玄小玉, 王爱民, 李建辉, 王建祥. SP1和UBE2C在食管鳞癌中的表达与临床病理特征的相关性研究[J]. 河北医学, 2025, 31(11): 1919-1923.
JIANG Haibin, WU Jianlong, ZHANG Bingxin, et al. Correlation of SP1 and UBE2C Expression with Clinicopathological Features in Esophageal Squamous Carcinoma. HeBei Med, 2025, 31(11): 1919-1923.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2025.11.027 或 http://www.hbyxzzs.cn/CN/Y2025/V31/I11/1919

[1] 谭劲松,熊黎,张若兰,等.LAD1在食管鳞癌发生发展中的作用及其分子机制[J].基因组学与应用生物学,2024,43(5):890-906.
[2] Ko KP,Huang Y,Zhang S,et al.Key genetic determinants driving esophageal squamous cell carcinoma initiation and immune evasion[J].Gastroenterology,2023,165(3):613-628.
[3] Wang X,Ling X,Wang C,et al. Response to neoadjuvant immune checkpointinhibitors and chemotherapy in Chinese patients with esophageal squamous cellcarcinoma:the role of tumor immune microenvironment[J].Cancer Immunol Immunother,2023,72(6):1619-1631.
[4] 黄红芳,卢香云,孙梦菲,等.SP1在食管鳞癌组织中的表达及其对食管鳞状细胞增殖和凋亡的影响[J].安徽医科大学学报,2023,58(12):2031-2037.
[5] Ardalan Khales S,Forghanifard MM,Abbaszadegan MR,et al.EZH2deregulates BMP,hedgehog,and hippo cell signaling pathways in esophagealsquamous cell carcinoma[J].Adv Med Sci,2023,68(1):21-30.
[6] 赵旸,谢佳翊,王华.UBE2C对宫颈癌HeLa细胞增殖、迁移及侵袭能力的影响[J].现代肿瘤医学,2022,30(12):2124-2128.
[7] Morgan E,Soerjomataram I,Rumgay H,et al.The global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040:new estimates from GLOBOCAN 2020[J].Gastroenterology,2022,163(3):649-658.
[8] Waters JK,Reznik SI.Update on management of squamous cell esophageal cancer[J].Curr Oncol Rep,2022,24(3):375-385.
[9] An L,Li M,Jia Q.Mechanisms of radiotherapy resistance andradiosensitization strategies for esophageal squamous cell carcinoma[J].MolCancer,2023,22(1):140.
[10] Zhou M,Bao S,Gong T,et al.The transcriptional landscape and diagnostic potential of long non-coding RNAsin esophageal squamous cell carcinoma[J].Nat Commun,2023,14(1):3799.
[11] Yang W,Cheng B,Chen P,et al.BTN3A1 promotes tumorprogression and radiation resistance in esophageal squamous cell carcinoma byregulating ULK1-mediated autophagy[J].Cell Death Dis,2022,13(11):984.
[12] Song D,Wei Y,Hu Y,et al.Identification of immunophenotypes in esophageal squamous cell carcinoma basedon immune gene sets[J].Clin Transl Oncol,2022,24(6):1100-1114.
[13] Zeng TT,Deng TH,Liu Z,et al.HN1L/AP-2γ/PLK1 signaling drives tumor progression and chemotherapyresistance in esophageal squamous cell carcinoma[J].Cell Death Dis,2022,13(12):1026.
[14] Chen X,Chen J,Yu X,et al.FOXM1 Promotes malignant proliferationof esophageal squamous cell carcinoma through transcriptional activating CDC6[J].DNA Cell Biol,2022,41(7):671-682.
[15] Kuang X,Liu Z.Mining the biomarkers and associated-drugs for esophageal squamous cell carcinoma by bioinformatic methods[J].Tohoku Exp Med,2022,256(1):27-36.
[16] 刘盈,黄凤祥,陈红杰,等.基于数据库挖掘UBE2C在肺腺癌中的表达及其临床意义[J].中南大学学报(医学版),2020,45(9):1044-1052.
[17] 黄美玲.Sp1介导miR-375调控头颈鳞癌生长和侵袭的实验研究[D].中南大学,2014.